Evidence map›Paper›PMID 37610452›Full record

ArticleParasitology research2023

Sulfadiazine analogs: anti-Toxoplasma in vitro study of sulfonamide triazoles.

Fadwa M Arafa, Doaa Hassan Osman, Mona Mohamed Tolba, Nadjet Rezki, Mohamed R Aouad, Mohamed Hagar, Mervat Osman, Heba Said

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Parasitology research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. iScience · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fadwa M ArafaDepartment of Medical Parasitology, Faculty of Medicine, Alexandria University, Alexandria, 21577, Egypt. f_arafa10@alexmed.edu.eg.
Doaa Hassan OsmanDepartment of Parasitology, Medical Research Institute, Alexandria University, Alexandria, 21561, Egypt.
Mona Mohamed TolbaDepartment of Parasitology, Medical Research Institute, Alexandria University, Alexandria, 21561, Egypt.
Nadjet RezkiDepartment of Chemistry, College of Science, Taibah University, Al-Madinah Al-Munawarah, 30002, Saudi Arabia.
Mohamed R AouadDepartment of Chemistry, College of Science, Taibah University, Al-Madinah Al-Munawarah, 30002, Saudi Arabia.
Mohamed HagarDepartment of Chemistry, Faculty of Science, Alexandria University, Alexandria, 21321, Egypt.
Mervat OsmanDepartment of Parasitology, Medical Research Institute, Alexandria University, Alexandria, 21561, Egypt.
Heba SaidDepartment of Parasitology, Medical Research Institute, Alexandria University, Alexandria, 21561, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toxoplasmosis is an infection that prevails all over the world and is caused by the obligate intracellular protozoan parasite Toxoplasma gondii (T. gondii). Promising novel compounds for the treatment of T. gondii are introduced in the current investigation. In order to test their in vitro potency against T. gondii tachyzoites, six 1,2,3-triazoles-based sulfonamide scaffolds with terminal NH

Indexed as

SulfadiazineToxoplasmaSulfanilamideSulfonamidesTriazolesSulfadiazineSulfanilamideSulfonamidesTriazoles1,2,3-triazolesClick chemistryIn vitro studySEMTEMToxoplasma gondii

Identifiers

PMID37610452
PMCPMC10495491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.